Viral suppression off ART using dual bNAb therapy
The RIO study is looking at whether a new type of treatment can keep viral load undetectable without ART. This will involve asking all participants to stop ART for a short time.
The study will measure how long viral load stays undetectable without ART. It will also look at what happens to the HIV virus and immune system in blood samples. When virus becomes detectable in a blood test (viral rebound) you will be asked to re-start your ART.
Latest News
- Dr Ming Lee, RIO Trial Physician, appearance on the STI Podcast, IAS Conference Feedback 2023After presenting at the 2023 HIV Cure & Immunotherapy Forum held alongside International AIDS Society (IAS) 2023, the 12th IAS … Read more […]
- Dr Ming Lee (RIO Trial physician) talk on bNAbs in clinical trials at IAS 2023, Brisbane.Our RIO Clinical Research Fellow at Imperial College London and Imperial College Healthcare NHS Trust, Dr Ming Lee, was invited … Read more […]
- Prof Sarah Fidler in Imperial College London podcast for Pride Month13 June 2023 To celebrate Pride Month, Imperial College London has published a series of podcasts exploring stigma and the … Read more […]
RIO is funded by the Bill & Melinda Gates Foundation. Imperial College London is the Trial Sponsor and the trial is coordinated by Imperial College London, The University of Oxford and The Rockefeller University.
